# US 2025/0049924 A1 · Abuse-Deterrent Pharmaceutical Composition with Aversion Properties

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049924 A1
- Document ID: US20250049924A1
- Status: Published application
- Kind: A1
- Application number: 18/924,880
- Filed: 2024-10-23
- Published: 2025-02-13
- Earliest claimed: 2022-04-27
- Assignees: Aardvark Therapeutics Inc.
- Applicants: Aardvark Therapeutics Inc.
- Inventors: Jane Wu LEE; Tien-Li LEE
- Web page: https://patentgrep.com/patent/US20250049924A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61K 9/1611: {Inorganic compounds}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

There is disclosed an improved abuse-deterrent pharmaceutical composition comprising a controlled pharmaceutical substance in a formulation comprising at least two gel-forming excipients selected from the group consisting of PEG ester, poloxamer, water-soluble anionic polysaccharide, and carboxymethylcellulose, and a bitter-agonist compound selected from the group consisting of denatonium salts (including denatonium acetate (DA), denatonium benzoate (DB), denatonium chloride, denatonium citrate, denatonium maleate, denatonium saccharide, and denatonium tartrate) chlorpheniramine, diphenidol, famotidine, haloperidol, quinine, parthenolide, and aristolochic acid. Preferably, the controlled pharmaceutical substance is an amphetamine or a pharmaceutically acceptable salt thereof. Preferably, the bitter receptor agonist is a denatonium salt selected from DA, DB, denatonium chloride, denatonium citrate, denatonium maleate, denatonium saccharide, and denatonium tartrate provided at from about 0.5 mg per dose administered to about 10 mg per dose administered. There is further disclosed a use for denatonium acetate (DA) as a pharmaceutical grade aversive agent to be added to abuse-deterrent formulations to deter snorting or smoking a controlled pharmaceutical substance at a dose of about 0.5 mg to about 10 mg per dose.

## Claims

### Claim 1

An abuse-deterrent pharmaceutical composition comprising a controlled pharmaceutical substance selected from the group consisting of amphetamine, dextroamphetamine, metylphenidate, amobarbital, secobarbital, butalbital/acetomenophen or aspirin/caffeine, dydrocodone, oxycodone, oxymorphone, morphine, codeine, fentanyl, alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, zolpidem, zaleplon, and eszopiclone, in a formulation comprising at least two gel-forming excipients selected from the group consisting of PEG ester, poloxamer, water-soluble anionic polysaccharide, and carboxymethylcellulose, and a bitter-agonist compound selected from the group consisting of denatonium salts, denatonium acetate (DA), denatonium benzoate (DB), denatonium chloride, denatonium citrate, denatonium maleate, denatonium saccharide, and denatonium tartrate, chlorpheniramine, diphenidol, famotidine, haloperidol, quinine, parthenolide, and aristolochic acid.

### Claim 2 (depends on 1)

The abuse-deterrent pharmaceutical composition of claim 1, wherein the bitter receptor agonist is a denatonium salt selected from DA, DB, denatonium chloride, denatonium citrate, denatonium maleate, denatonium saccharide, and denatonium tartrate.

### Claim 3 (depends on 2)

The abuse-deterrent pharmaceutical composition of claim 2, wherein the concentration of denatonium in the improved abuse-deterrent pharmaceutical composition is about 50 ppm.

### Claim 4 (depends on 3)

The abuse-deterrent pharmaceutical composition of claim 3, wherein the denatonium salt is denatonium acetate monohydrate (DA) at a dose administered/snorted of from about 0.5 mg to about 10 mg of total DA.

### Claim 5 (depends on 4)

The abuse-deterrent pharmaceutical composition of claim 4, wherein the (DA) at a dose administered/snorted of from about 0.5 mg to about 10 mg of total DA.

### Claim 6 (depends on 4)

The abuse-deterrent and aversive formulation of claim 4, wherein the gel forming excipients are selected from the group consisting of PEG ester, poloxamer, water-soluble anionic polysaccharide, and carboxymethylcellulose.

### Claim 7 (depends on 6)

The abuse-deterrent and aversive formulation of claim 6, wherein the PEG ester is polyoxyl stearate.

### Claim 8 (depends on 6)

The abuse deterrent and aversive formulation of claim 6, wherein the poloxamer is poloxamer 124.

### Claim 9 (depends on 6)

The abuse-deterrent and aversive formulation of claim 6, wherein the water-soluble anionic polysaccharide is gellan gum.

### Claim 10 (depends on 1)

The abuse deterrent and aversive formulation of claim 1, the ratio of poloxamer:polysaccharide:PEG ever is about 40:30:30.
